Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2012

View Archived Issues

EMERGE study results presented for pegylated interferon lambda-1a

Gene therapy rescues retinal degeneration in Prom1 knockout mice

Gene therapy shows promise for retinal degeneration

GlaxoSmithKline patents novel CRAC inhibitors

U.S. team develops new immunogenic polypeptides for HIV infection

Lupin synthesizes novel voltage-gated sodium channel blockers

Merck KGaA designs new MetAP 2 inhibitors

Presidio Pharmaceuticals discloses new compounds targeting NS5A protein

Biomarkers of inflammation are associated with AMD severity

S1 Biopharma expands focus

Early clinical data for ABT-267 monotherapy and combination treatment shows promise

Biovest plans to seek European marketing approval for cancer vaccine

New phase III Lu-AA-21004 data in MDD support planned regulatory filings

Bristol-Myers Squibb establishes first discovery collaboration in China

Newron completes phase III program for safinamide, signs new licensing agreement

Maxygen to receive payment from Bayer HealthCare for factor VIIa program

Resminostat enters clinical development in Japan

KineMed and CHDI Foundation enter biomarker collaboration

Livatag begins phase III trial for liver cancer

Fibrocell Science submits protocol to FDA for azficel-T study

Cyclacel gives update on phase II/III sapacitabine study

IDRI finds partner for tuberculosis vaccine candidate

Scil Proteins enters into collaboration with Ono Pharmaceutical

L-DOS-47 begins phase I/II study for NSCLC

Furiex enters into licensing agreements for Priligy

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...